NovoCure Ltd (NVCR) FY2025 10-K Annual Report
NovoCure Ltd (NVCR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
NovoCure Ltd FY2025 10-K Analysis
Business Overview
- • Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
- • New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
Management Discussion & Analysis
- • Revenue and profitability details not provided in the provided MD&A excerpt
- • No segment performance data disclosed
Risk Factors
- • FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
- • Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
NovoCure Ltd FY2025 Key Financial MetricsXBRL
Revenue
$655M
▲ +8.3% YoY
Net Income
-$136M
▲ +19.2% YoY
Gross Margin
74.5%
▼ -280bp YoY
Operating Margin
-23.5%
▲ +470bp YoY
Net Margin
-20.8%
▲ +708bp YoY
ROE
-40.0%
▲ +681bp YoY
Total Assets
$804M
▼ -35.2% YoY
EPS (Diluted)
$-1.22
▲ +21.8% YoY
Operating Cash Flow
-$49M
▼ -85.9% YoY
Source: XBRL data from NovoCure Ltd FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on NovoCure Ltd
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.